Sains Malaysiana 55(8)(2026): 1272-1283

http://doi.org/10.17576/jsm-2026-5508-04
 

Emerging Immunohistochemical Biomarkers Beyond Prostate Specific Antigen in Prostate Cancer

(Kemunculan Penanda Bioimunohistokimia Melangkaui Antigen Khusus Prostat dalam Kanser Prostat)

 

HUMA AFZAL, NOSHEEN ASLAM*, GHULAM MUSTAFA & SHAZIA ANWER BUKHARI

 

Department of Biochemistry, Government College University Faisalabad, Pakistan

 

Diserahkan: 13 Mac 2026/Diterima: 3 Ogos 2026

 

Abstract

Prostate cancer remains a significant health concern, particularly among the older male population. Proper differentiation between malignant adenocarcinoma and benign prostatic diseases is critical for successful diagnosis. This study aimed to determine the dependability of immunohistochemistry (IHC) markers specifically AMACR, p63, and Cytokeratin as a means of diagnosing cancer. The diagnostic value of HOXB13 gene variants and MYC mRNA expression in tissues with benign prostatic hyperplasia (BPH) was also evaluated. The research involved patients with clinical indicators of prostate dysfunction and high PSA values. Tissue specimens were tested using the PIN-4 cocktail (IHC) and Hematoxylin & Eosin (H&E) staining. The ethanol-preserved prostate cancer tissue samples were homogenized to extract total RNA using the Gene JET RNA Purification Kit based on silica membranes and adjusted for high-purity RNA extraction. The concentration and purity of the extracted RNA were evaluated, and only samples exhibiting an A260/A280 ratio within the range of 1.8 to 2.0 were deemed appropriate for downstream analyses. Histopathology confirmed prostatic adenocarcinoma in all cases, mostly low-grade with a minor group of intermediate-grade malignancies. These findings support the notion that IHC markers, specifically AMACR combined with a basal cell marker, are useful modalities for distinguishing between benign and malignant prostate tumors. It also suggests that the rare rs8556 variant is functionally important and potentially deleterious. In prostate cancer treatment, this technique can potentially assist in earlier diagnosis, reduced uncertainty in diagnosis, and personalized treatment.

Keywords: Gene expression; prostate cancer; RNA extraction; Sanger sequencing

Abstrak

Kanser prostat kekal sebagai masalah kesihatan yang utama, terutamanya dalam kalangan populasi lelaki tua. Pembezaan yang betul antara adenokarsinoma malignan dan penyakit prostat benigna adalah penting untuk diagnosis yang berjaya. Kajian ini bertujuan untuk menentukan kebergantungan penanda imunohistokimia (IHC) khususnya AMACR, p63 dan Sitokeratin sebagai cara untuk mendiagnosis kanser. Nilai diagnostik varian gen HOXB13 dan pengekspresan mRNA MYC dalam tisu dengan hiperplasia prostat benigna (BPH) juga dinilai. Penyelidikan ini melibatkan pesakit dengan petunjuk klinikal disfungsi prostat dan nilai PSA yang tinggi. Spesimen tisu diuji menggunakan pewarnaan koktel PIN-4 (IHC) dan Hematoxylin & Eosin (H&E). Sampel tisu kanser prostat yang diawet etanol dihomogenkan untuk mengekstrak RNA total menggunakan Kit Penulenan RNA Gene JET berdasarkan membran silika dan diselaraskan untuk pengekstrakan RNA berketulenan tinggi. Kepekatan dan ketulenan RNA yang diekstrak dinilai dan hanya sampel yang menunjukkan nisbah A260/A280 dalam julat 1.8 hingga 2.0 dianggap sesuai untuk analisis hiliran. Histopatologi mengesahkan adenokarsinoma prostat dalam semua kes, kebanyakannya gred rendah dengan sekumpulan kecil malignan gred pertengahan. Penemuan ini menyokong tanggapan bahawa penanda IHC, khususnya AMACR yang digabungkan dengan penanda sel basal, adalah modaliti yang penting untuk membezakan antara tumor prostat benigna dan malignan. Ia juga menunjukkan bahawa varian rs8556 yang jarang berlaku adalah penting secara fungsi dan berpotensi merosakkan. Dalam rawatan kanser prostat, teknik ini berpotensi membantu dalam diagnosis lebih awal, mengurangkan ketidakpastian dalam diagnosis dan rawatan yang diperibadikan.

Kata kunci: Ekspresi gen; kanser prostat; pengekstrakan RNA; penjujukan Sanger

 

RUJUKAN

Ahmed, H.U., Bosaily, A.E-S., Brown, L.C., Gabe, R., Kaplan, R., Parmar, M.K., Collaco-Moraes, Y., Ward, K., Hindley, R.G., Freeman, A., Kirkham, A.P., Oldroyd, R., Parker, C., Emberton, M. & PROMIS study group. 2017. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. The Lancet 389(10071): 815-822.

Arikawa, E., Sun, Y., Wang, J., Zhou, Q., Ning, B., Dial, S.L., Guo, L. & Yang, J. 2008. Cross-platform comparison of SYBR® Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics 9(1): 328.

Blessin, N.C., Yang, C., Mandelkow, T., Raedler, J.B., Li, W., Bady, E., Simon, R., Vettorazzi, E., Lennartz, M., Bernreuther, C., Fraune, C., Jacobsen, F., Krech, T., Marx, A., Lebok, P., Minner, S., Burandt, E., Clauditz, T.S., Wilczak, W., Sauter, G., Heinzer, H., Haese, A., Schlomm, T., Graefen, M. & Steurer, S. 2023. Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry. The Journal of Pathology 260(1): 5-16.

Carroll, Jennifer E., Jennifer A. Emond,  Linda L. Griffin, Elizabeth R. Bertone-Johnson, Nicole A. VanKim and Susan R. Sturgeon. 2024. Children's Perception of Food Marketing Across Digital Media Platforms.  American Journal of Preventive Medicine Focus 3 (3): 1-9.

Crawford, D.E., Schellhammer, P.F., McLeod, D.G., Moul, J.W., Higano, C.S., Shore, N., Denis, L., Iversen, P., Eisenberger, M.A. & Labrie, F. 2018. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. Journal of Urology 200(5): 956-966.

Glenn, W.K., Ngan, C.C., Amos, T.G., Edwards, R.J., Swift, J., Lutze-Mann, L., Shang, F., Whitaker, N.J. & Lawson, J.S. 2017. High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer. Infectious Agents and Cancer 12(1): 46.

Hofman, M.S., Lawrentschuk, N., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J.M., Frydenberg, M., Shakher, R., Wong, L.M., Taubman, K., Ting Lee, S., Hsiao, E., Roach, P., Nottage, M., Kirkwood, I., Hayne, D., Link, E., Marusic, P., Matera, A., Herschtal, A., Iravani, A., Hicks, R.J., Williams, S., Murphy, D.G.; proPSMA Study Group Collaborators. 2020. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. The Lancet 395(10231): 1208-1216.

Höti, N., Lih, T-S., Dong, M., Zhang, Z., Mangold, L., Partin, A.W., Sokoll, L.J., Li, Q.K. & Zhang, H. 2023. Urinary PSA and serum PSA for aggressive prostate cancer detection. Cancers 15(3): 960.

Hupe, M.C., Philippi, C., Roth, D., Kümpers, C., Ribbat-Idel, J., Becker, F., Joerg, V., Duensing, S., Lubczyk, V.H., Kirfel, J., Sailer, V., Kuefer, R., Merseburger, A.S., Perner, S. & Offermann, A. 2018. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Frontiers in Oncology 8: 623.

Kasivisvanathan, V., Rannikko, A.S., Borghi, M., Panebianco, V., Mynderse, L.A., Vaarala, M.H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R.G., Roobol, M.J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G.M., Virdi, J., Boxler, S., Robert, G., Singh, P.B., Venderink, W., Hadaschik, B.A., Ruffion, A., Hu, J.C., Margolis, D., Crouzet, S., Klotz, L., Taneja, S.S., Pinto, P., Gill, I., Allen, C., Giganti, F., Freeman, A., Morris, S., Punwani, S., Williams, N.R., Brew-Graves, C., Deeks, J., Takwoingi, Y., Emberton, M. & Moore, C.M. for the PRECISION Study Group Collaborator. 2018. MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine 378(19): 1767-1777.

Klein, E.A., M.R., Cooperberg, C., Magi-Galluzzi, J.P., Simko, S.M., Falzarano, T., Maddala, J.M. Chan, Li, J., Cowan, J.E., Tsiatis, A.C., Cherbavaz, D.B., Pelham, R.J., Tenggara-Hunter, I., Baehner, F.L., Knezevic, D., Febbo, P.G., Shak, S., Kattan, M.W., Lee, M. & Carroll, P.R. 2014. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urology 66(3): 550-560.

Kolijn, K., Verhoef, E.I. & van Leenders, G.J. 2015. Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget 6(27): 24488-24498.

Mamidala, P., Rajarapu, S.P., Jones, S.C. & Mittapalli, O. 2011. Identification and validation of reference genes for quantitative real-time polymerase chain reaction in Cimex lectularius. Journal of Medical Entomology 48(4): 947-951.

McKiernan, J., Donovan, M.J., O’Neill, V., Bentink, S., Noerholm, M., Belzer, S., Skog, J., Kattan, M.W., Partin, A., Andriole, G., Brown, G., Wei, J.T., Thompson Jr., I.M. & Carroll, P. 2016. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncology 2(7): 882-889.

Mori, R., Wang, Q., Danenberg, K.D., Pinski, J.K. & Danenberg, P.V. 2008. Both β‐actin and GAPDH are useful reference genes for normalization of quantitative RT‐PCR in human FFPE tissue samples of prostate cancer. The Prostate 68(14): 1555-1560.

Obafemi, F.A. & Umahi-Ottah, G. 2023. A review of global cancer prevalence and therapy. J. Cancer Res. Treat. Prev. 1(3): 128-147.

Oseni, S.O., Naar, C., Pavlović, M., Asghar, W., Hartmann, J.X., Fields, G.B., Esiobu, N. & Kumi-Diaka, J. 2023. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: Prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers 15(12): 3110.

Peng, Y-C., Lin, Y-C., Hung, Y-L., Fu, C-C., Chang, M.D-T., Lin, Y-Y. & Chou, T-Y. 2022. Rapid histological assessment of prostate specimens in the three-dimensional space by hydrophilic tissue clearing and confocal microscopy. Journal of Histochemistry & Cytochemistry 70(8): 597-608.

Rendek, T., Pos, O., Duranova, T., Saade, R., Budis, J., Repiska, V. & Szemes, T. 2024. Current challenges of methylation-based liquid biopsies in cancer diagnostics. Cancers 16(11): 2001.

Rodríguez, A., Duyvejonck, H., Van Belleghem, J.D., Gryp, T., Van Simaey, L., Vermeulen, S., Van Mechelen, E. & Vaneechoutte, M. 2020. Comparison of procedures for RNA-extraction from peripheral blood mononuclear cells. PLoS ONE 15(2): e0229423.

Sanchis, P., Sabater, A., Lechuga, J., Rada, J., Seniuk, R., Pascual, G., Gatti, M., Bizzotto, J., Shepherd, P.D.A., Yang, J., Cotignola, J., Vazquez, E., Mateo, J., Valacco, P., Labanca, E., Logothetis, C., Gueron, G. & Anselmino, N. 2025. PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression. Oncogene 44(38): 3568-3579.

Sanguedolce, F., Cormio, A., Zanelli, M., Palicelli, A., Zizzo, M., Falagario, U.G., Mazzucchelli, R., Galosi, A.B., Carrieri, G. & Cormio, L. 2025. Diagnostic workout of glandular malignant lesions of the bladder according to the 5th WHO classification. Critical Reviews in Clinical Laboratory Sciences 62(4): 301-312.

Spratt, D.E., Yousefi, K., Deheshi, S., Ross, A.E., Den, R.B., Schaeffer, E.M., Trock, B.J., Zhang, J., Glass, A.G., Dicker, A.P., Abdollah, F., Zhao, S.G., Lam, L.L.C., du Plessis, M., Choeurng, V., Haddad, Z., Buerki, C., Davicioni, E., Weinmann, S., Freedland, S.J., Klein, E.A., Karnes, R.J. & Feng, F.Y. 2017. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. Journal of Clinical Oncology 35(18): 1991-1998.

Tektemur, A., Ozaydin, S., Onalan, E.E., Kaya, N., Kuloglu, T., Ozercan, İ.H., Tekin, S. & Mohammed Elyas, H. 2019. TRPM2 mediates disruption of autophagy machinery and correlates with the grade level in prostate cancer. Journal of Cancer Research & Clinical Oncology 145(5): 1297-1311.

Trick, A.Y., Chen, F-E., Schares, J.A., Freml, B.E., Lor, P., Yun, Y. & Wang, T-H. 2021. High resolution estimates of relative gene abundance with quantitative ratiometric regression PCR (qRR-PCR). Analyst 146(21): 6463-6469.

Van Neste, L., Hendriks, R.J., Dijkstra, S., Trooskens, G., Cornel, E.B., Jannink, S.A., de Jong, H., Hessels, D., Smit, F.P., Melchers, W.J.G., Leyten, G.H.J.M., de Reijke, T.M., Vergunst, H., Kil, P., Knipscheer, B.C., Hulsbergen-van de Kaa, C.A., Mulders, P.F.A., van Oort, I.M., Van Criekinge, W. & Schalken, J.A. 2016. Detection of high-grade prostate cancer using a urinary molecular biomarker–based risk score. European Urology 70(5): 740-748.

Vollnberg, B., Alberts, I., Genitsch, V., Rominger, A. & Afshar-Oromieh, A. 2022. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F] PSMA-1007 PET/CT for prostate cancer - A single-centre experience of PET-guided biopsies. European Journal of Nuclear Medicine and Molecular Imaging 49(11): 3910-3916.

Wan, J.C.M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J.D., Caldas, C., Pacey, S., Baird, R. & Rosenfeld, N. 2017. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer 17(4): 223-238.

Wilson, T.K. & Zishiri, O.T. 2024. Prostate cancer: A review of genetics, current biomarkers and personalised treatments. Cancer Reports 7(10): e70016.

Yang, G., Goltsov, A.A., Ren, C., Kurosaka, S., Edamura, K., Logothetis, R., DeMayo, F.J., Troncoso, P., Blando, J., DiGiovanni, J. & Thompson, T.C. 2012. Caveolin-1 upregulation contributes to c-Myc–induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Molecular Cancer Research 10(2): 218-229.

Zhai, Q. & Deng, F.M. 2021. Diagnostic values of immunohistochemistry in bladder cancer. In Urinary Bladder Pathology, edited by Zhou, H., Guo, C.C. & Ro, J.Y. Springer, Cham. pp. 159-173.

Zhang, H., Yan, Z., Wang, X., Ganova, M., Chang, H., Lassakova, S., Korabecna, M. & Neuzil, P. 2021. Determination of advantages and limitations of qPCR duplexing in a single fluorescent channel. ACS Omega 6(34): 22292-22300.

 

*Pengarang untuk surat-menyurat; email: nosheenaslam@gcuf.edu.pk